Novel drug delivery systems are advanced technologies designed to improve the therapeutic performance of drugs by controlling their pharmacokinetics, biodistribution, and target-site accumulation. These systems overcome many limitations of conventional drug delivery, including poor solubility, rapid clearance, non-specific toxicity, and insufficient concentration at the target site. By engineering the carrier rather than the drug molecule itself, novel delivery systems can transform existing drugs into more effective therapies and enable the development of entirely new classes of treatments.
Liposomes
Liposomes are spherical vesicles composed of one or more phospholipid bilayers surrounding an aqueous core. They can encapsulate both hydrophilic drugs in the aqueous interior and lipophilic drugs within the bilayer. Liposomal drug delivery offers several advantages: improved drug solubility, protection from enzymatic degradation, prolonged circulation time, and reduced toxicity through altered biodistribution. The first liposomal drug approved by the FDA was Doxil (liposomal doxorubicin) in 1995 for Kaposi sarcoma, which significantly reduced the cardiotoxicity associated with free doxorubicin. Ambisome (liposomal amphotericin B) followed, reducing nephrotoxicity of the antifungal agent. Surface modification with polyethylene glycol (PEG) creates stealth liposomes that evade recognition by the reticuloendothelial system, further extending circulation time.
Nanoparticles
Nanoparticles are solid colloidal particles ranging from ten to one thousand nanometers in diameter, composed of polymers, lipids, or inorganic materials. Polymeric nanoparticles can be engineered from biodegradable polymers such as polylactic-co-glycolic acid (PLGA) to provide sustained release over days to weeks. Lipid nanoparticles have gained prominence as delivery vehicles for nucleic acid therapeutics, exemplified by the mRNA COVID-19 vaccines. Nanoparticles can be functionalized with targeting ligands on their surface to achieve active targeting to specific cells or tissues. The enhanced permeability and retention (EPR) effect enables passive accumulation of nanoparticles in tumor tissue due to leaky vasculature. Challenges include large-scale manufacturing reproducibility, sterilization, and the potential for nanoparticle aggregation during storage.
Microparticles
Microparticles are particles with diameters from one to one thousand micrometers used primarily for sustained release of drugs over extended periods. Injectable microparticle formulations of leuprolide acetate (Lupron Depot) provide controlled release for one to six months, enabling treatment of prostate cancer and endometriosis with infrequent injections. Microparticles are typically manufactured by double emulsion-solvent evaporation or spray drying techniques. The release profile is governed by polymer degradation and drug diffusion through the matrix. Key advantages over daily injections include improved patient compliance and stable drug levels. Limitations include the need for reconstitution before injection, potential for injection site reactions, and the irreversibility of administration once the dose is injected.
Transdermal Technologies
Transdermal drug delivery administers drugs through the skin for systemic effect, avoiding first-pass hepatic metabolism and providing sustained drug levels. Passive transdermal patches have been successfully used for drugs such as nicotine, fentanyl, and scopolamine. However, the stratum corneum barrier limits passive delivery to small, lipophilic, potent molecules. Active transdermal technologies overcome this limitation. Iontophoresis uses a mild electrical current to drive charged drug molecules across the skin, enabling controlled, on-demand delivery. Sonophoresis uses low-frequency ultrasound to increase skin permeability. Microneedle arrays create microscopic channels in the skin through which drug can diffuse, combining the convenience of a patch with the delivery capability of a hypodermic needle. These technologies are expanding the range of drugs deliverable transdermally, including peptides and vaccines.
Targeted Drug Delivery
Targeted drug delivery aims to concentrate the therapeutic agent at the disease site while minimizing exposure to healthy tissue. Active targeting functionalizes the drug carrier surface with ligands — antibodies, peptides, aptamers, or small molecules — that recognize receptors overexpressed on target cells. Antibody-drug conjugates are a powerful example of targeted delivery, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Binding the drug carrier to the target cell is only the first step; the drug must then be internalized and released intracellularly to exert its effect. Passive targeting exploits the EPR effect for tumor accumulation and is enhanced by controlling particle size, shape, and surface properties.
Theranostics
Theranostics combines therapy and diagnostics into a single platform, enabling simultaneous treatment and monitoring of disease response. A theranostic nanoparticle may carry a chemotherapeutic agent together with an imaging contrast agent, allowing the physician to visualize drug distribution, assess target engagement, and adjust the treatment regimen in real time. This approach is most advanced in oncology, where multifunctional nanoparticles can deliver chemotherapy, provide magnetic resonance or fluorescence imaging, and respond to external stimuli such as heat or light to trigger drug release. Theranostics represents a step toward personalized medicine by enabling treatment individualization based on the patient’s specific disease characteristics.
Future Directions
The field of novel drug delivery continues to evolve rapidly. Stimuli-responsive or smart systems release drug in response to environmental triggers such as pH, temperature, enzyme activity, or redox potential — exploiting differences between diseased and healthy tissues. Biomimetic delivery systems cloak nanoparticles in cell membranes to evade immune recognition and enhance targeting. RNA delivery technologies, including lipid nanoparticles for siRNA and mRNA, have matured dramatically. The convergence of drug delivery with gene therapy, immunotherapy, and digital health is opening new therapeutic possibilities. Manufacturing scalability, cost, and regulatory pathways for combination products remain active areas of development.
Conclusion
Novel drug delivery systems have transformed the pharmaceutical landscape by enabling existing drugs to reach their full therapeutic potential and by making possible entirely new treatment modalities such as nucleic acid therapies. Liposomes, nanoparticles, transdermal technologies, and targeted delivery systems each offer unique advantages for specific therapeutic applications. As the science of materials engineering and biological targeting advances, drug delivery systems will continue to play a central role in the future of medicine.
